Literature DB >> 33975583

Trends of cervical cancer at global, regional, and national level: data from the Global Burden of Disease study 2019.

Xingxing Zhang1, Qingle Zeng2, Wenwen Cai1, Weiqing Ruan3.   

Abstract

BACKGROUND: Cervical cancer is an important global health problem. In this study we aimed to analyze trends in cervical cancer at the global, regional, and national levels from 1990 to 2019, to inform health service decision-making.
METHODS: Data on cervical cancer was extracted from the Global Burden of Disease study, 2019. Trends in cervical cancer burden were assessed based on estimated annual percentage change (EAPC) and age-standardized rate (ASR).
RESULTS: Globally, decreasing trends were observed in incidence, death, and disability adjusted life years (DALYs) of cervical cancer from 1990 to 2019, with respective EAPCs of - 0.38 (95% confidence interval [CI]: - 0.41 to - 0.34), - 0.93 (95%CI: - 0.98 to - 0.88), and - 0.95 (95 CI%: - 1.00 to - 0.90). Meanwhile, decreasing trends were detected in most sociodemographic index (SDI) areas and geographic regions, particularly death and DALYs in Central Latin America, with respective EAPCs of - 2.61 (95% CI: - 2.76 to - 2.46) and - 2.48 (95% CI: - 2.63 to - 2.32); hhowever, a pronounced increasing trend in incidence occurred in East Asia (EAPC = 1.33; 95% CI: 1.12 to 1.55). At the national level, decreasing trends in cervical cancer were observed in most countries/territories, particularly DALYs in the Maldives (EAPC = - 5.06; 95% CI: - 5.40 to - 4.72), Whereas increasing trends were detected in Lesotho, Zimbabwe, and Bulgaria.
CONCLUSIONS: Slowly decreasing trends in cervical cancer were detected worldwide from 1990 to 2019. Cervical cancer remains a substantial health problem for women globally, requiring more effective prevention and control strategies.

Entities:  

Keywords:  Cervical cancer; Global Health; Global burden of disease; Health services; Quality-adjusted life years

Year:  2021        PMID: 33975583      PMCID: PMC8114503          DOI: 10.1186/s12889-021-10907-5

Source DB:  PubMed          Journal:  BMC Public Health        ISSN: 1471-2458            Impact factor:   3.295


Introduction

Cervical cancer is the fourth leading cause of cancer death among women worldwide [1, 2]. It is estimated that there were 570,000 new cases and 311,000 deaths of women (particularly middle-aged women) from cervical cancer globally in 2018 [3, 4]. The distribution of cervical cancer differs across the world, with than 85% of deaths occurring in developing regions [5]. Over 90% of the highest incidence rates of cervical cancer occur in sub-Saharan Africa [6]. The drastic changes in epidemiological patterns of cervical cancer, over recent decades have been attributed to the effectiveness of the Papanicolaou (Pap) test in improving detection of the human papilloma virus (HPV) [7]. For example, Finland launched an nationwide screening programmer for cervical cancer in 1960, which led to a steep decrease in the rate of cervical cancer (to below 1/100,000) from 1973 [8]. Australia has established an HPV vaccination program covering more than 70% of girls and boys aged 12–13 years nationwide, and the incidence of high-grade cervical dysplasia in girls < 18 years old reduced by 38% [9]. In contrast, the incidence of cervical cancer in the former Soviet Union has risen significantly, due to weak health care systems and inadequate screening programs [10]. Currently, three types of prophylactic vaccines, the bivalent, quadrivalent, and 9-valent HPV vaccine formulations, have been approved for use in many countries [11], and it is estimated that increased vaccine coverage will greatly accelerate the decline in incidence of and death from cervical cancer [12]. In conclusion, cervical cancer epidemiological patterns have changed dramatically over recent decades, emphasizing the importance of tracking changing trends in this context. Therefore, the authors estimated the global, regional, and national trends in cervical cancer from 1990 to 2019, using the data from the latest version of the Global Burden of Disease study (GBDs), to inform health care strategies.

Methods

Data source

The GBDs provides a methodological and conceptual framework for estimation and quantification of health loss worldwide, which facilitates the assessment of progress and challenges in disease control. In this work, the cervical cancer burden was mainly considered in terms of incidence, death, and DALYs. The subject term, ‘cervical cancer’, was explored using the Global Health Data Exchange (GHDx) query tool (http://ghdx.healthdata.org/gbd-results-tool), including the following parameters: time interval, age groups, and geographic locations. Cervical cancer burden data (rate, number of cases) were extracted according to age, sociodemographic index (SDI) areas, geographic regions, and countries/territories, from 1990 to 2019, without any inclusion/exclusion criteria. According to SDI, regions and countries were classified into five categories: low, low-middle, middle, high-middle, and high. Data were available from 21 geographic regions and 204 countries/territories worldwide. Human Development Index (HDI) data were obtained from the United Nations Development Program (http://hdr.undp.org/en /data).

Statistical analysis

Age-standardization is a necessary when considering differences in the age structure of multiple populations over time. Age-standardized rate (ASR) was estimated using the following formula: where, a represents the age-specific rate in the ith age group, w represents the number of people (or the weight) in the respective ith age group from among the selected standard population, and A represents the number of age groups. The estimated annual percentage change (EAPC) is a widely accepted index to quantify and describe the trend in ASR [13]. A regression line was fitted to the natural logarithm of the rates (ASR). EAPC and its 95% confidence interval (CI) were estimated using a linear regression model. The formulae was as follows: where y = ln (ASR) and x = calendar year. Trends were assessed as follows: 1. EAPC and its 95% CI > 0 signified an increasing trend in ASR; 2. EAPC value and its 95% CI < 0 signified a decreasing trend in ASR; 3. Other outcomes signified that ASR was stable over time. To explore the impact factors of EAPC, the relationship between EAPCs values and ASR in 1990, and between EAPC values and HDI in 2019, were assessed using the Pearson correlation analysis. Data were analyzed using R program (Lucent Technologies, Jasmine Mountain, USA; Version 3.6.2). A p value of < 0.05 was considered to be statistically significant.

Results

Trends in the incidence of cervical cancer

There were 565.54 × 103 (95% uncertainty interval [UI]: 481.52 × 103 to 636.43 × 103) incident cases of cervical cancer in the world in 2019, representing an increase of 68.50% since 1990. The overall age-standardized incidence rate (ASIR) showed a downward trend between 1990 and 2019, decreasing by an annual average of 0.38% per year (EAPC = − 0.38; 95% CI: − 0.41 to − 0.34) (Table 1 and Fig. 1). Increasing percentage changes in number were detected in all age groups, with the highest alteration in the groups aged > 80 (118.81%) and 50–54 (90.42%) years (Supplementary Table 1 and Fig. 2 a). Meanwhile, analysis according to SDI showed decreasing trends in all areas, particularly those with high SDI (EAPC = − 0.95; 95% CI: − 1.05 to − 0.85) (Table 1 and Fig. 2 b). Among geographic regions, East Asia (115.38 × 103) had the most cases in 2019. The incident trends in cervical cancer decreased in most areas, of which the most pronounced were Central Latin America (EAPC = − 1.77; 95% CI: − 1.92 to − 1.62), followed by Tropical Latin America and South Asia. Increasing trends occurred only in East Asia and Southern Sub-Saharan Africa, where EAPCs rates were 1.33 (95% CI: 1.12 to 1.55) and 0.28 (95% CI: 0.06 to 0.51), respectively (Table 1 and Fig. 2 c). Among 204 countries/territories, the ASR in 2019 varied from 108.8 per 100,000 population in Kiribati to 2.84 per 100,000 population in Egypt (Fig. 3 a). The largest increase in the incident number occurred in the United Arab Emirates (501.27%) and Saudi Arabia (453.6%). Conversely, the largest decreases were observed in Denmark (− 46.30%) and Latvia (− 45.66%). The ASIR of cervical cancer showed decreasing trends in 151 countries/territories, with the greatest decreases in the Maldives, Taiwan, and Singapore, with respective EAPCs of − 3.68 (95% CI: − 4.00 to − 3.35), − 3.63 (95% CI: − 3.96 to − 3.30), and − 3.40 (95% CI: − 3.61 to − 3.18). In contrast, increasing trends were observed in 28 countries, particularly Lesotho, Italy, and China, with respective EAPCs of 3.43 (95% CI: 2.90 to 3.95), 2.02 (95% CI: 1.70 to 2.34), and 1.61 (95% CI: 1.36 to 1.86) (Supplementary Table 2 and Fig. 3 b-c).
Table 1

The number and age-standardized rate of cervical cancer incidence in global, sexes, SDI areas and geographic regions in 1990 and 2019, and percentage change of absolute number and the EAPCs from 1990 to 2019

Characteristics199020191990–2019
Number ×103 (95% UI)ASR/100,000) (95% UI)Number ×103 (95% UI)ASR/100,000) (95% UI)Change innumber (%)EAPC(95%CI)
Overall335.64 (300.35–393.89)14.91 (13.37–17.55)565.54 (481.52–636.43)13.35 (11.37–15.03)68.50− 0.38(− 0.41–-0.34)
SDI
 Low41.50 (31.77–50.80)27.74 (21.56–34.25)78.82 (61.61–97.93)23.21 (18.31–28.76)89.94−0.69(− 0.73–-0.65)
 Low-middle66.22 (54.06–81.76)18.04 (14.86–22.49)125.96 (107.88–150.11)15.78 (13.57–18.87)90.23−0.56(− 0.65–-0.47)
 Middle92.18 (81.45–116.40)14.87 (13.17–18.85)183.34 (144.49–208.86)13.44 (10.61–15.28)98.89−0.29(− 0.33–-0.24)
 High-middle75.80 (71.53–88.88)12.77 (12.05–15)113.12 (89.78–129.15)11.59 (9.18–13.24)49.23−0.27(− 0.31–-0.22)
 High59.69 (54.3–61.65)11.83 (10.67–12.22)63.86 (55.71–71.45)8.91 (7.74–9.99)6.99−0.95(−1.05–-0.85)
Regions
 East Asia45.26 (35.38–79.36)9.00 (7.08–15.63)115.38 (64.35–147.12)11.17 (6.25–14.26)154.941.33 (1.12–1.55)
 South Asia56.36 (44.21–68.59)16.04 (12.64–19.66)100.02 (80.11–124.77)12.37 (9.94–15.46)77.48−1.09(−1.29–-0.90)
 Southeast Asia31.13 (23.52–38.68)18.75 (14.3–23.63)52.06 (41.93–68.67)14.48 (11.73–19)67.26−1.06(−1.17–-0.96)
 Central Asia5.27 (4.9–5.63)18.58 (17.37–19.85)7.67 (6.65–8.83)16.00 (13.94–18.4)45.34−0.34(− 0.45–-0.23)
 High-income Asia Pacific12.47 (11.64–14.36)11.65 (10.81–13.42)15.06 (11.91–17.96)10.33 (7.99–12.4)20.82−0.17(− 0.27–-0.06)
 Oceania0.57 (0.4–0.76)29.58 (21.39–39.83)1.33 (0.86–1.82)28.22 (19–38.09)133.17−0.05(− 0.12–0.03)
 Australasia1.37 (1.15–1.47)11.83 (9.76–12.65)1.65 (1.27–2.11)8.22 (6.32–10.59)20.06−0.98(−1.36–-0.6)
 Eastern Europe22.82 (19.67–24.65)14.53 (12.66–15.79)23.00 (18.91–28.03)14.76 (11.91–18.14)0.770.03(−0.12–0.18)
 Western Europe28.60 (25.91–29.68)11.19 (9.88–11.62)27.17 (22.69–31.7)8.26 (6.85–9.68)−4.99−0.97(−1.07–-0.88)
 Central Europe15.39 (14.39–16.21)20.67 (19.23–21.74)13.68 (11.26–15.9)15.80 (12.97–18.48)−11.14−1.08(− 1.21–-0.96)
 High-income North America17.53 (15.11–18.26)10.39 (8.89–10.83)21.85 (17.42–26.62)8.93 (7.09–10.93)24.65−0.58(−0.71–-0.44)
 Andean Latin America4.10 (3.45–4.86)33.39 (28.20–39.63)9.10 (6.93–11.61)29.74 (22.67–37.83)121.97−0.53(−0.66–-0.41)
 Central Latin America17.08 (15.8–17.85)32.30 (29.43–33.73)28.48 (23.11–35.03)21.45 (17.44–26.37)66.74−1.77(−1.92–-1.62)
 Caribbean4.12 (3.33–4.72)28.00 (22.69–31.86)6.86 (5.36–8.50)26.23 (20.41–32.58)66.57−0.24(−0.30–-0.19)
 Tropical Latin America14.12 (13.36–16.36)24.52 (23.12–28.28)23.74 (22.13–27.18)17.91 (16.69–20.43)68.15−1.29(−1.39–-1.19)
 Southern Latin America6.48 (6.05–6.87)26.30 (24.53–27.91)9.84 (7.27–12.85)24.85 (18.23–32.74)51.93−0.38(−0.52–-0.25)
 Eastern Sub-Saharan Africa19.08 (14.41–23.81)38.27 (28.81–47.55)36.33 (25.76–48.45)31.79 (22.9–41.68)90.43−0.80(−0.87–-0.73)
 Southern Sub-Saharan Africa6.17 (4.68–7.53)33.33 (25.19–40.62)12.02 (9.74–14.44)32.90 (26.88–39.48)94.800.28 (0.06–0.51)
 Western Sub-Saharan Africa14.85 (11.66–18.64)28.64 (22.59–35.8)33.37 (26.14–42.54)25.47 (20.17–31.94)124.75−0.35(−0.40–-0.31)
 North Africa and Middle East7.003 (5.03–8.03)6.90 (4.92–7.88)14.63 (11.14–17.63)5.78 (4.43–6.89)107.98−0.63(−0.72–-0.54)
 Central Sub-Saharan Africa5.84 (3.95–7.83)37.38 (25.91–49.42)12.30 (8.23–16.88)32.32 (21.74–44.74)110.47−0.51(− 0.61–-0.41)

EAPC Estimated annual percentage change, ASR Age-standardized rate, CI Confidence interval, UI Uncertainty interval, SDI Socio-demographic index. Percentage change in absolute number was calculated based on the crew data

Fig. 1

The trends in incidence, death, and DALYs of cervical cancer globally, and in SDI areas and geographic regions from 1990 to 2019. SDI, sociodemographic index; DALYs, disability-adjusted life years

Fig. 2

The distribution of the incident number of cervical cancer worldwide, and in SDI areas and geographic regions from 1990 to 2019. a the incident number in age groups; b the ASR in SDI areas; c the incident number in geographical regions. SDI, sociodemographic index; ASR, age-standardized rate

Fig. 3

The distribution of ASR, percentage changes in number, and EAPCs of cervical cancer incidence at the national level, 1990–2019. The follows were a the ASR in 2019; b the percentage changes in number between 2000 and 2019; c the EAPCs in countries/territories, respectively. Countries/territories with an extreme value were annotated. ASR, age-standardized rate; EAPC, estimated annual percentage change

The number and age-standardized rate of cervical cancer incidence in global, sexes, SDI areas and geographic regions in 1990 and 2019, and percentage change of absolute number and the EAPCs from 1990 to 2019 EAPC Estimated annual percentage change, ASR Age-standardized rate, CI Confidence interval, UI Uncertainty interval, SDI Socio-demographic index. Percentage change in absolute number was calculated based on the crew data The trends in incidence, death, and DALYs of cervical cancer globally, and in SDI areas and geographic regions from 1990 to 2019. SDI, sociodemographic index; DALYs, disability-adjusted life years The distribution of the incident number of cervical cancer worldwide, and in SDI areas and geographic regions from 1990 to 2019. a the incident number in age groups; b the ASR in SDI areas; c the incident number in geographical regions. SDI, sociodemographic index; ASR, age-standardized rate The distribution of ASR, percentage changes in number, and EAPCs of cervical cancer incidence at the national level, 1990–2019. The follows were a the ASR in 2019; b the percentage changes in number between 2000 and 2019; c the EAPCs in countries/territories, respectively. Countries/territories with an extreme value were annotated. ASR, age-standardized rate; EAPC, estimated annual percentage change

Trends in death caused by cervical cancer

The overall number of deaths caused by cervical cancer was 184.53 × 103 (95% UI: 164.84 × 103 to 218.94 × 103) in 2019, representing a 52.00% increase since 1990. The age-standardized death rate (ASDR) showed a decreasing trend from 1990 to 2019, with an annual average reduction of 0.93% per year (EAPC = − 0.93; 95% CI: − 0.98 to − 0.88) (Supplementary Table 3 and Fig. 1). Decreasing percentage changes were found in younger age groups, with the highest in the 15–19-year-old age group (− 23.71%) (Supplementary Table 1 and Supplementary Figure 1A). The ASDR showed a downward trend in all SDI areas, particularly high SDI areas (EAPC = − 1.57; 95% CI: − 1.68 to − 1.46) (Supplementary Table 3 and Supplementary Figure 1B). Geographically, the largest number of deaths was observed in South Asia (1833.69 × 103) in 2019. Downward trends were observed in most regions, particularly Central and Latin America (EAPC = − 2.61; 95% CI: − 2.76 to − 2.46), followed by Tropical Latin America and Western Europe. Increasing trends only occurred in Southern Sub-Saharan Africa, in which EAPCs were 0.46 (95% CI: 0.19 to 0.72) (Supplementary Table 3 and Supplementary Figure 1C). Among 204 countries/territories, the highest ASR in 2019 occurred in Kiribati (69.52 per 100,000 population) and the lowest in Kuwait (1.76 per 100,000 population) (Supplementary Figure 3A). The most significant increases in numbers of deaths were noted in the United Arab Emirates (349.67%) and Guatemala (276.37%). In contrast, the largest decreases were observed in the Ukraine (− 50.7%) and Denmark (− 48.58%). Decreasing trends in ASDR were detected in 174 countries/territories, particularly the Maldives, Taiwan, and Singapore, in which the respective EAPCs were − 4.54 (95% CI: − 4.86 to − 4.22), − 4.13 (95% CI: − 4.44 to − 3.82), and − 4.04(95% CI: − 4.26 to − 3.81). Conversely, increasing trends were observed in 30 countries, notably Lesotho, Zimbabwe, and Bulgaria, with respective EAPCs of 3.25 (95% CI: 2.72 to 3.77), 1.46 (95% CI: 0.95 to 1.97), and 1.20 (95% CI: 0.92 to 1.48) (Supplementary Table 4 and Supplementary Figure 3B-C).

Trends in DALYs caused by cervical cancer

During the period 1990–2019, the number of DALYs caused by cervical cancer increased by 44.99% to 8955.01 × 103 (95% UI: 7547.73 × 103 to 9978.46 × 103) in 2019. The ASR of DALYs had a downward trend from 1990 to 2019, with an annual average of 0.95% (EAPC = − 0.95; 95% CI: − 1.00 to − 0.90) (Supplementary Table 5 and Fig. 1). There were decreasing percentage changes in DALYs in younger age groups, with largest in the 15–19-year-old age group (− 22.89%) (Supplementary Table 1 and Supplementary Figure 2A). DALYs attributable to cervical cancer showed decreasing trends in all SDI areas, and particularly high SDI areas (EAPC = − 1.62; 95% CI: − 1.74 to − 1.49) (Supplementary Table 5 and Supplementary Figure 2B). At the regional level in 2019, the greatest number of DALYs was in South Asia (1833.69 × 103) The ASR of DALYs showed decreasing trends in most regions, particularly Central Latin America (EAPC = − 2.48; 95% CI: − 2.63 to − 2.32), followed by Tropical Latin America (EAPC = − 1.95; 95% CI: − 2.05 to − 1.85) and Australasia (EAPC = − 1.83; 95% CI: − 2.26 to − 1.41). Increasing trends occurred only in East Asia and Southern Sub-Saharan Africa, with respective EAPCs of 0.02 (95% CI: − 0.20 to 0.24) and 0.23 (95% CI: − 0.04 to 0.51) (Supplementary Table 5 and Supplementary Figure 2C). The country with the highest ASR in 2019 was Kiribati (2143.06 per 100,000 population), and that with the lowest was Kuwait (44.34 per 100,000 population) (Supplementary Figure 4A). The largest increases in DALYs were observed in the United Arab Emirates (409.36%), Qatar (264.9%), and Guatemala (264.9%). Conversely, the largest decreases were in Denmark (− 46.30%), Latvia (− 45.66%), and Ukraine (− 50.22%). In general, DALYs attributable to cervical cancer were decreasing in 177 countries, with the most obvious downward trend in the Maldives (EAPC = − 5.06; 95% CI: − 5.4 to − 4.72), followed by Taiwan (EAPC = − 4.43; 95% CI: − 4.76 to − 4.11), and Singapore (EAPC = − 4.31; 95% CI: − 4.55 to − 4.07). In contrast, increasing trends were observed in 27 countries, specifically Lesotho, Zimbabwe, and Bulgaria, with respective EAPCs of 3.44 (95% CI: 2.87 to 4.02), 1.67 (95% CI: 1.09 to 2.26), and 1.23 (95% CI: 0.95 to 1.51) (Supplementary Table 6 and Supplementary Figure 4B-C).

Analysis of factors influencing EAPC

During the period 1990–2019, EAPCs were positively associated with ASR death and DALYs attributable to cervical cancer (ρ = 0.16, P = 0.02; ρ = 0.15, P = 0.034, respectively) (Fig. 4 a-b). Further, EAPCs were negatively associated with HDI in 2019 in incidence, death, and DALYs attributable to cervical cancer (ρ = − 0.29, P < 0.001; ρ = 0.42, P < 0.001; ρ = 0.39, p < 0.001, respectively) (Fig. 5 a-c).
Fig. 4

The correlation between EAPCs and ASR in 1990 at the national level. The EAPCs of death (a), and DALYs (b) had positive associations with ASR in 1990, respectively. The association was calculated with Pearson correlation analysis. The size of circle is increased with the numbers in 1990. EAPC, estimated annual percentage change; ASR, age-standardized rate. DALYs, disability-adjusted life years

Fig. 5

The correlation between EAPCs and HDI in 2019 at the national level. The EAPCs of incidence (a), death (b), and DALYs (c) had negative associations with HDI in 2019, respectively. The association was calculated with Pearson correlation analysis. The size of circle is increased with the numbers in 2019. EAPC, estimated annual percentage change; ASR, age-standardized rate. DALYs, disability-adjusted life years

The correlation between EAPCs and ASR in 1990 at the national level. The EAPCs of death (a), and DALYs (b) had positive associations with ASR in 1990, respectively. The association was calculated with Pearson correlation analysis. The size of circle is increased with the numbers in 1990. EAPC, estimated annual percentage change; ASR, age-standardized rate. DALYs, disability-adjusted life years The correlation between EAPCs and HDI in 2019 at the national level. The EAPCs of incidence (a), death (b), and DALYs (c) had negative associations with HDI in 2019, respectively. The association was calculated with Pearson correlation analysis. The size of circle is increased with the numbers in 2019. EAPC, estimated annual percentage change; ASR, age-standardized rate. DALYs, disability-adjusted life years

Discussion

Decreasing trends in cervical cancer were observed worldwide from 1990 to 2019. The declining trends were predominantly a result of effective precautionary procedures combined with a series of sociocultural factors, including access to health care, changes in marriage age and family planning behavior, and enhancements in education [14]. Cervical cancer occurred across a range of ages; our data showed that the 50–54 years age group had the largest number of cases, suggesting infection at a younger age and slow progression to cancer [15]. The decreasing incidence rate of cervical cancer in young women is attributable to increasing coverage of vaccination against common subtypes of HPV [16]; however, the decreasing trends were slow, which was probably related to behavioral factors, including smoking, use of oral contraception, and promiscuous sexual behaviors [17-19]. Cervical cancer is the malignancy with the largest inter-country range of variation in mortality among all cancers [20]. Morbidity of cervical cancer is closely related to socioeconomic level; it was the highest in developing countries (e.g. Southern Sub-Saharan Africa) in 2019, which can be explained by limitations in knowledge, screening services, and sexual behavior [21, 22]. In contrast, the lowest cervical cancer ASIR was observed in North Africa and the Middle East, which may be due to cultural factors and conservative sexual behaviors [23]. These regions also have low rates of other sexually related infections, such as HIV [24]. In general, decreasing trends in the incidence of cervical cancer were observed in most countries, with the most obvious downward trend s in the Maldives, Taiwan, and Singapore, due to cancer screening and HPV programs financed by huge government expenditure. The Maldives, Taiwan and Singapore launched national screening programs in 2014, 2004 and 1995, respectively, which greatly reduced the risk of cervical cancer [25-27]. However, increasing trends still appeared in some countries, particularly Lesotho, Italy, and China. Poverty, weak health systems, and low education levels are obstacles in Lesotho [28]. China has the largest population worldwide, and also had the highest incidence, mortality and DALYs from cervical cancer [29], which may reflect a deficiency in Pap testing in China [30]. Due to the overload of public immunization systems, vaccination coverage in 15-year-old girls has decreased in Italy over recent years [31]. Further, an online survey reported that Italian undergraduates had poor knowledge about HPV [32]. The GBD study conducted high quality assessment of cervical cancer based on good quality and quantity of data; however, this paper has some limitations: (1) vital registration and cancer registry data are poor and heterogeneous in many low-income regions, due to different screening methods, which may lead to underestimation bias in these cancer registries [33]; and (2) when actual disease burden data was not available, GBD uncertainty estimates were used to fills the gaps. In addition, this type of analysis is inevitably influenced by differences in data collection and coding as well as data source quality [34].

Conclusions

Cervical incidence, death and DALYs showed decreasing trends at the global, regional, and national levels from 1990 to 2019; however, the trends were relatively slow, and there were large regional imbalance. Consequently, cervical cancer remains a major public health problem, and development of more effective prevention and management strategies is warranted. Additional file 1: Supplementary Figure 1. The distribution of death number of cervical cancer worldwide, and in SDI areas and geographic regions from 1990 to 2019. Additional file 2: Supplementary Figure 2. The distribution of DALYs number of cervical cancer worldwide, and in SDI areas and geographic regions from 1990 to 2019. Additional file 3: Supplementary Figure 3. The distribution of ASR, percentage changes in number, and EAPCs of death caused by cervical cancer at the national level, 1990-2019. Additional file 4: Supplementary Figure 4. The distribution of ASR, percentage changes in number, and EAPCs of DALYs caused by cervical cancer at the national level, 1990-2019. Additional file 5: Supplementary Table 1. the number of cervical cancer in 2019, and the percentage changes in number during the period 1990-2019 in age groups. Additional file 6: Supplementary Table 2. the number and age–standardized rate of cervical cancer incidence at national level and both sexes in 1990 and 2019, and the percentage changes in number and the EAPCs from 1990 to 2019. Additional file 7: Supplementary Table 3. The number and age-standardized rate of death due to cervical cancer in global, sexes, SDI areas and geographic regions in 1990 and 2019, and percentage change of absolute number and the EAPCs from 1990 to 2019. Additional file 8: Supplementary Table 4. the number and age-standardized rate of death caused by cervical cancer at national level and both sexes in 1990 and 2019, and the percentage changes in number and the EAPCs from 1990 to 2019. Additional file 9: Supplementary Table 5. The number and age-standardized rate of DALYs due to cervical cancer in global, sexes, SDI areas and geographic regions in 1990 and 2019, and percentage change of absolute number and the EAPCs from 1990 to 2019. Additional file 10: Supplementary Table 6. the number and age-standardized rate of DALYs caused by cervical cancer at national level and both sexes in 1990 and 2019, and the percentage changes in number and the EAPCs from 1990 to 2019.
  33 in total

1.  Perianal Bowen disease in a child with human immunodeficiency virus.

Authors:  Kathleen A Carroll; Jeffrey Pierce; Carrie L Kovarik
Journal:  Pediatr Dermatol       Date:  2010 Mar-Apr       Impact factor: 1.588

Review 2.  Cervical cancer worldwide.

Authors:  Mailinh Vu; Jim Yu; Olutosin A Awolude; Linus Chuang
Journal:  Curr Probl Cancer       Date:  2018-06-25       Impact factor: 3.187

3.  Human papillomavirus vaccine against cervical cancer: Opportunity and challenge.

Authors:  Renjie Wang; Wei Pan; Lei Jin; Weiming Huang; Yuehan Li; Di Wu; Chun Gao; Ding Ma; Shujie Liao
Journal:  Cancer Lett       Date:  2019-12-05       Impact factor: 8.679

4.  Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline.

Authors:  H Hirte; E B Kennedy; L Elit; M Fung Kee Fung
Journal:  Curr Oncol       Date:  2015-06       Impact factor: 3.677

5.  Worldwide burden of cervical cancer in 2008.

Authors:  M Arbyn; X Castellsagué; S de Sanjosé; L Bruni; M Saraiya; F Bray; J Ferlay
Journal:  Ann Oncol       Date:  2011-04-06       Impact factor: 32.976

6.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

Review 7.  Too many women are dying from cervix cancer: Problems and solutions.

Authors:  David K Gaffney; Mia Hashibe; Deanna Kepka; Kathryn A Maurer; Theresa L Werner
Journal:  Gynecol Oncol       Date:  2018-10-06       Impact factor: 5.482

8.  Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.

Authors:  Marc Arbyn; Elisabete Weiderpass; Laia Bruni; Silvia de Sanjosé; Mona Saraiya; Jacques Ferlay; Freddie Bray
Journal:  Lancet Glob Health       Date:  2019-12-04       Impact factor: 26.763

9.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.

Authors:  Christina Fitzmaurice; Christine Allen; Ryan M Barber; Lars Barregard; Zulfiqar A Bhutta; Hermann Brenner; Daniel J Dicker; Odgerel Chimed-Orchir; Rakhi Dandona; Lalit Dandona; Tom Fleming; Mohammad H Forouzanfar; Jamie Hancock; Roderick J Hay; Rachel Hunter-Merrill; Chantal Huynh; H Dean Hosgood; Catherine O Johnson; Jost B Jonas; Jagdish Khubchandani; G Anil Kumar; Michael Kutz; Qing Lan; Heidi J Larson; Xiaofeng Liang; Stephen S Lim; Alan D Lopez; Michael F MacIntyre; Laurie Marczak; Neal Marquez; Ali H Mokdad; Christine Pinho; Farshad Pourmalek; Joshua A Salomon; Juan Ramon Sanabria; Logan Sandar; Benn Sartorius; Stephen M Schwartz; Katya A Shackelford; Kenji Shibuya; Jeff Stanaway; Caitlyn Steiner; Jiandong Sun; Ken Takahashi; Stein Emil Vollset; Theo Vos; Joseph A Wagner; Haidong Wang; Ronny Westerman; Hajo Zeeb; Leo Zoeckler; Foad Abd-Allah; Muktar Beshir Ahmed; Samer Alabed; Noore K Alam; Saleh Fahed Aldhahri; Girma Alem; Mulubirhan Assefa Alemayohu; Raghib Ali; Rajaa Al-Raddadi; Azmeraw Amare; Yaw Amoako; Al Artaman; Hamid Asayesh; Niguse Atnafu; Ashish Awasthi; Huda Ba Saleem; Aleksandra Barac; Neeraj Bedi; Isabela Bensenor; Adugnaw Berhane; Eduardo Bernabé; Balem Betsu; Agnes Binagwaho; Dube Boneya; Ismael Campos-Nonato; Carlos Castañeda-Orjuela; Ferrán Catalá-López; Peggy Chiang; Chioma Chibueze; Abdulaal Chitheer; Jee-Young Choi; Benjamin Cowie; Solomon Damtew; José das Neves; Suhojit Dey; Samath Dharmaratne; Preet Dhillon; Eric Ding; Tim Driscoll; Donatus Ekwueme; Aman Yesuf Endries; Maryam Farvid; Farshad Farzadfar; Joao Fernandes; Florian Fischer; Tsegaye Tewelde G/Hiwot; Alemseged Gebru; Sameer Gopalani; Alemayehu Hailu; Masako Horino; Nobuyuki Horita; Abdullatif Husseini; Inge Huybrechts; Manami Inoue; Farhad Islami; Mihajlo Jakovljevic; Spencer James; Mehdi Javanbakht; Sun Ha Jee; Amir Kasaeian; Muktar Sano Kedir; Yousef S Khader; Young-Ho Khang; Daniel Kim; James Leigh; Shai Linn; Raimundas Lunevicius; Hassan Magdy Abd El Razek; Reza Malekzadeh; Deborah Carvalho Malta; Wagner Marcenes; Desalegn Markos; Yohannes A Melaku; Kidanu G Meles; Walter Mendoza; Desalegn Tadese Mengiste; Tuomo J Meretoja; Ted R Miller; Karzan Abdulmuhsin Mohammad; Alireza Mohammadi; Shafiu Mohammed; Maziar Moradi-Lakeh; Gabriele Nagel; Devina Nand; Quyen Le Nguyen; Sandra Nolte; Felix A Ogbo; Kelechi E Oladimeji; Eyal Oren; Mahesh Pa; Eun-Kee Park; David M Pereira; Dietrich Plass; Mostafa Qorbani; Amir Radfar; Anwar Rafay; Mahfuzar Rahman; Saleem M Rana; Kjetil Søreide; Maheswar Satpathy; Monika Sawhney; Sadaf G Sepanlou; Masood Ali Shaikh; Jun She; Ivy Shiue; Hirbo Roba Shore; Mark G Shrime; Samuel So; Samir Soneji; Vasiliki Stathopoulou; Konstantinos Stroumpoulis; Muawiyyah Babale Sufiyan; Bryan L Sykes; Rafael Tabarés-Seisdedos; Fentaw Tadese; Bemnet Amare Tedla; Gizachew Assefa Tessema; J S Thakur; Bach Xuan Tran; Kingsley Nnanna Ukwaja; Benjamin S Chudi Uzochukwu; Vasiliy Victorovich Vlassov; Elisabete Weiderpass; Mamo Wubshet Terefe; Henock Gebremedhin Yebyo; Hassen Hamid Yimam; Naohiro Yonemoto; Mustafa Z Younis; Chuanhua Yu; Zoubida Zaidi; Maysaa El Sayed Zaki; Zerihun Menlkalew Zenebe; Christopher J L Murray; Mohsen Naghavi
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

Review 10.  Prevention of Cervical Cancer in Sub-Saharan Africa: The Advantages and Challenges of HPV Vaccination.

Authors:  Eleanor Black; Robyn Richmond
Journal:  Vaccines (Basel)       Date:  2018-09-08
View more
  22 in total

Review 1.  The role of LncRNA MCM3AP-AS1 in human cancer.

Authors:  Shirin Azizidoost; Farhoodeh Ghaedrahmati; Mohadeseh Sheykhi-Sabzehpoush; Shahab Uddin; Mehri Ghafourian; Abdolah Mousavi Salehi; Mona Keivan; Maryam Cheraghzadeh; Zahra Nazeri; Maryam Farzaneh; Seyed Esmaeil Khoshnam
Journal:  Clin Transl Oncol       Date:  2022-08-24       Impact factor: 3.340

2.  Predictive Value of the Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) Index on the Oncological Outcomes of Locally Advanced Cervical Cancer Patients.

Authors:  Kittinun Leetanaporn; Jitti Hanprasertpong
Journal:  Cancer Manag Res       Date:  2022-06-14       Impact factor: 3.602

Review 3.  Mapping Evidence on the Burden of Breast, Cervical, and Prostate Cancers in Sub-Saharan Africa: A Scoping Review.

Authors:  Alfred Musekiwa; Maureen Moyo; Mohanad Mohammed; Zvifadzo Matsena-Zingoni; Halima Sumayya Twabi; Jesca Mercy Batidzirai; Geoffrey Chiyuzga Singini; Kabelo Kgarosi; Nobuhle Mchunu; Portia Nevhungoni; Patricia Silinda; Theodora Ekwomadu; Innocent Maposa
Journal:  Front Public Health       Date:  2022-06-16

Review 4.  Review of the Standard and Advanced Screening, Staging Systems and Treatment Modalities for Cervical Cancer.

Authors:  Siaw Shi Boon; Ho Yin Luk; Chuanyun Xiao; Zigui Chen; Paul Kay Sheung Chan
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

5.  [Late toxicity after adjuvant radiotherapy for cervical cancer-comparison of conventional radiation therapy with image-guided intensity-modulated radiotherapy].

Authors:  G G Grabenbauer; Artem Trofymov
Journal:  Strahlenther Onkol       Date:  2022-04-25       Impact factor: 4.033

Review 6.  Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer.

Authors:  Supitcha Kamolratanakul; Punnee Pitisuttithum
Journal:  Vaccines (Basel)       Date:  2021-11-30

7.  Attitude towards HPV Vaccination and the Intention to Get Vaccinated among Female University Students in Health Schools in Jordan.

Authors:  Malik Sallam; Kholoud Al-Mahzoum; Huda Eid; Areej M Assaf; Maram Abdaljaleel; Mousa Al-Abbadi; Azmi Mahafzah
Journal:  Vaccines (Basel)       Date:  2021-12-03

8.  Leveraging HIV Care Infrastructures for Integrated Chronic Disease and Pandemic Management in Sub-Saharan Africa.

Authors:  Marie A Brault; Sten H Vermund; Muktar H Aliyu; Saad B Omer; Dave Clark; Donna Spiegelman
Journal:  Int J Environ Res Public Health       Date:  2021-10-13       Impact factor: 3.390

9.  Awareness and Practices Related to Cervical Cancer among Females in Saudi Arabia.

Authors:  Heba M Zahid; Alma B Qarah; Amal M Alharbi; Arwa E Alomar; Shaimaa A Almubarak
Journal:  Int J Environ Res Public Health       Date:  2022-01-27       Impact factor: 3.390

Review 10.  A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies.

Authors:  Nasim Vahidfar; Saeed Farzanefar; Hojjat Ahmadzadehfar; Eóin N Molloy; Elisabeth Eppard
Journal:  Cancers (Basel)       Date:  2022-03-31       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.